Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Efficacy and Safety Study of Sonazoid™ and SonoVue® in Participants With Focal Liver Lesions, Undergoing Pre- and Post-Contrast Ultrasound Imaging

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03335566
Recruitment Status : Completed
First Posted : November 7, 2017
Results First Posted : August 27, 2018
Last Update Posted : October 31, 2018
Sponsor:
Information provided by (Responsible Party):
GE Healthcare

Brief Summary:
The purpose of this study is to compare the efficacy of Sonazoid™ and SonoVue® in participants with focal liver lesions (FLLs), by comparing pre-and post-contrast ultrasound examination findings with regard to various aspects of lesion diagnosis including diagnosis as benign versus malignant, specific lesion diagnosis, confidence in diagnosis, and quality of delineation of lesion-related blood vessels (from images obtained during vascular imaging) and detection of lesion presence and quality of delineation of the whole liver (from images obtained during whole liver imaging).

Condition or disease Intervention/treatment Phase
Liver Lesions Drug: Sonazoid™ Drug: SonoVue® Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 424 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: A Phase 3 Multicentre, Randomised, Comparative Study of the Efficacy and Safety of the Ultrasound Contrast Agents Sonazoid™ and SonoVue® in Subjects With Focal Liver Lesions Undergoing Pre- and Post-Contrast Ultrasound Imaging
Actual Study Start Date : May 11, 2014
Actual Primary Completion Date : April 9, 2015
Actual Study Completion Date : April 9, 2015

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Sonazoid™
Participants will receive single intravenous (I.V) bolus injection of Sonazoid™ 0.12 microliter (µL) microbubbles (MB)/kilogram (kg) body weight.
Drug: Sonazoid™
Single Dose of Sonazoid™ 0.12 µL MB/kg as I.V. injection.

Active Comparator: SonoVue®
Participants will receive single I.V bolus injection of SonoVue® 2.4 milliliter (mL).
Drug: SonoVue®
Single Dose of SonoVue® 2.4 mL as I.V. injection.




Primary Outcome Measures :
  1. Percentage of Participants With Accuracy Improvement in Post-Contrast Versus Pre-Contrast Ultrasound (US) Examination for Diagnosis of the Target Lesion as Malignant or Benign Against the Reference Diagnosis (RD)/Standard of Truth [ Time Frame: Pre-administration up to 15 minutes post-administration ]
    Accuracy improvement was calculated by the number of participants with improved diagnoses from the pre-contrast diagnosis to the post-contrast diagnosis divided by the total number of participants, multiplied by 100. Assessments were done by 3 blinded readers. Efficacy population which included all participants who received Sonazoid™ or SonoVue®, for whom pre-contrast & post-contrast images were recorded, & for whom there was a reference standard contrast-enhanced computed tomography (CECT)/contrast-enhanced magnetic resonance imaging (CE-MRI) examination or biopsy.


Secondary Outcome Measures :
  1. Number of Lesions Detected by Post-Contrast US Relative to Number of Lesions Detected by Pre-Contrast US (Both by Blinded Readers[BR]) and Number of Lesions Detected by Post-Contrast US (by BR) Relative to Number of Lesions Detected by RD (Investigators) [ Time Frame: Pre-administration up to 15 minutes post-administration ]
    For the cases that can be assessed by the blinded readers both pre- and post-contrast, differences were calculated between the Sonazoid™ and SonoVue® groups in the number of lesions detected during whole-liver imaging (post-contrast minus pre-contrast). The differences were also calculated between the Sonazoid™ and SonoVue® groups in the number of lesions (post-contrast minus reference diagnosis) detected during whole-liver imaging.

  2. Number of Participants With Diagnostic Confidence (Evaluated by Blinded Readers) in Pre-Contrast and Post-Contrast Ultrasound Examination Results [ Time Frame: Pre-administration up to 15 minutes post-administration ]
    Confidence in diagnoses from the pre- and post-contrast ultrasound examinations was evaluated based on 4-point scale: 0-Unknown (cannot make a judgement on level of confidence), 1- Not confident (another examination was required), 2- Probable (Would have more confidence if another diagnostic imaging test such as MRI or CT was performed), 3- Definite (Sufficient confidence to the extent that another diagnostic imaging test such as MRI or CT was unnecessary).

  3. Percentage of Participants With Accuracy Improvement in Post-contrast Versus Pre-contrast Ultrasound Examination for Lesion-Specific Diagnoses of the Target Lesion Against the Reference Diagnosis/Standard of Truth [ Time Frame: Pre-administration up to 15 minutes post-administration ]
    The accuracy improvement was calculated by the number of participants with improved diagnoses from the pre-contrast diagnosis to the post-contrast diagnosis divided by the total number of participants, multiplied by 100. Assessment was performed by 3 blinded readers.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria: Participants may be included in the study if they meet all of the following criteria:

  • Participant has at least 1 untreated focal liver lesions (FLL) but =<8 lesions (excluding cysts) <10 centimeter (cm) in diameter confirmed in a diagnostic examination performed in the past month (or past 3 months if lesion is benign) that can be visualised by non- contrast-enhanced (CE) ultrasound
  • Participant has had a dynamic CE-computed tomography (CE-CT) or CE-magnetic resonance imaging (CE-MRI) examination within the past month or is scheduled to have one in the month following inclusion in the study and the original images (or copies thereof) are/will be available. (This inclusion criterion does not apply for participants enrolled as training cases. Investigators will be asked to submit standard of truth/ reference diagnosis for training cases whenever possible, since the cases may be used for training and testing the blinded readers prior to the blinded read)
  • Participant is a 20- to 80-year-old inpatient or outpatient referred for an ultrasound examination of the liver
  • Participant is able and willing to comply with study procedures and will give their signed and dated informed consent
  • The participant, if female, is either surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), postmenopausal (cessation of menses for more than 1 year), or non-lactating, or if of childbearing potential the results of a serum or urine human chorionic gonadotropin pregnancy test, performed on the day of investigational medicinal product (IMP) administration (with the result known before IMP administration), are negative

Exclusion Criteria:

  • The participant has an acute clinically fatal condition (i.e., not expected to survive for at least 6 months)
  • The participant has previously received Sonazoid™ or has received SonoVue® within the past 30 days
  • The participant has undergone or is undergoing systemic or loco-regional chemotherapy, or radiation therapy
  • The participant is participating in another clinical trial with an unregistered medicinal product, or less than 30 days have passed since completing participation in such a trial
  • The participant has a history of allergies to eggs or egg products (i.e., manifested by full body rash, respiratory difficulty, oral or laryngeal swelling, hypotension or shock)
  • The participant has known hypersensitivity to sulphur hexafluoride or to any of the components of SonoVue®
  • The participant has undergone or plans to undergo liver biopsy or surgery within the 24 hours before or after this examination
  • The participant has undergone or plans to undergo an examination with a contrast agent (i.e., iodinated x-ray contrast agent, magnetic resonance imaging (MRI) contrast agent or another ultrasound contrast agent) within the 24 hours before or after this examination
  • The participant is considered to be unsuitable to participate in the study by the investigator
  • The participant is known to have a right-to-left shunt, severe pulmonary hypertension (pulmonary artery pressure >90 millimeter of mercury (mmHg) or uncontrolled systemic hypertension
  • The participant has a recent acute coronary syndrome or clinically unstable ischaemic cardiac disease, including: evolving or ongoing myocardial infarction, typical angina at rest within the last 7 days, significant worsening of cardiac symptoms within the last 7 days, recent coronary artery intervention or other factors suggesting clinical instability (e.g., recent deterioration of electrocardiogram [ECG], laboratory or clinical findings), acute cardiac failure, Class III/IV cardiac failure, or severe rhythm disorders
  • The participant has adult respiratory distress syndrome, severe emphysema, pulmonary vasculitis, or a history of pulmonary emboli
  • The participant has known thrombosis within the liver, portal, or mesenteric veins

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03335566


Locations
Layout table for location information
China, Beijing
Peking Union Medical College Hospital, East Campus: No.1 Shuaifuyuan Wangfujing
Dongcheng, Beijing, China, 100730
Chinese PLA General Hospital, No. 28 Fuxing Road
Haidan, Beijing, China, 100853
Peking Union Medical College Hospital, West Campus: No. 41 Damucang Hutong
Xicheng, Beijing, China, 100032
China, Guangdong
The First Affiliated Hospital, Sun-Yat sen University, No. 58 Zhongshan Second Road
Guangzhou, Guangdong, China, 510080
The Second Affiliated Hospital of Zhongshan University, No. 107 Yanjiang West Road
Guangzhou, Guangdong, China, 510120
China, Shanghai
Shanghai First Hospital, North Campus: No. 100 Haining Road
Hongkou, Shanghai, China, 200080
Shanghai First Hospital, South Campus: No.650 New Songjiang Road
Songjiang, Shanghai, China, 201620
Zhongshan Hospital Fudan University, No. 180 Fenglin Road
Xuhui, Shanghai, China, 200032
Shanghai Hua Shan Hospital, No. 12 Wulumuqi Middle Road
Xuhui, Shanghai, China, 200040
Shanghai Sixth Hospital, No. 600 Yishan Road
Xuhui, Shanghai, China, 200233
Shanghai Tenth People's Hospital, No. 301 Yanchang Middle Road
Zhabei, Shanghai, China, 200072
Korea, Republic of
Seoul National University Hospital, 101, Daehak-Ro, Jongno-Gu
Seoul, Korea, Republic of, 110-744
Seoul St Mary's Hospital, 222 Banpo-daero, Seocho-gu
Seoul, Korea, Republic of, 137-701
Taiwan
National Taiwan University Hospital - Yunlin Branch, No. 579, Sec. 2 Yunlin Road
Douliu, Yunlin County, Taiwan
National Taiwan University Hospital, No. 7 Chung-Shan South Road
Taipei, Taiwan, 100
Mackay Memorial Hospital, No. 92, Sec. 2 Zhongshan N. Road
Taipei, Taiwan, 10449
Cathay General Hospital, No. 280 Jen-Ai Road, Sec. 4
Taipei, Taiwan, 10650
Taipei Veterans General Hospital, No. 201 Shih-Pai Road, Sec. 2
Taipei, Taiwan, 112
Sponsors and Collaborators
GE Healthcare
Investigators
Layout table for investigator information
Study Chair: Francois Tranquart, MD, PhD GE Healthcare

Layout table for additonal information
Responsible Party: GE Healthcare
ClinicalTrials.gov Identifier: NCT03335566     History of Changes
Other Study ID Numbers: GE-045-002
GE-045-002 ( Other Identifier: GE HealthCare )
First Posted: November 7, 2017    Key Record Dates
Results First Posted: August 27, 2018
Last Update Posted: October 31, 2018
Last Verified: October 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No